Sandoz files Amgen biosimilar drug for osteoporosis
February 8, 2023Research and Development
Switzerland-based Sandoz has filed a proposed biosimilar of Amgen’s osteoporosis drug Prolia/Xgeva with the FDA. According to Sandoz, over 10 …
Cell and Gene Therapy Catapult to play significant role in establishing one of the largest life sciences campuses in Europe
February 8, 2023Business Services
London, 8th February 2023: The Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in …
Sequana Medical announces the successful completion of pre-clinical studies with its second-generation DSR product for congestive heart failure
February 8, 2023Business Services
Ghent, Belgium – 08 February 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana
AstraZeneca’s Forxiga approved in EU for chronic heart failure
February 7, 2023Medical Communications
AstraZeneca has announced that its drug, Forxiga, has been approved in the EU for the treatment of symptomatic chronic heart …
Genentech shares positive results from global phase 3 trials for crovalimab in PNH
February 7, 2023Medical Communications
Following the global COMMODORE 2 study, Genentech has announced positive data for crovalimab in treating patients with paroxysmal nocturnal haemoglobinuria …
4D Molecular Therapeutics’ Fabry Gene Therapy put on FDA-mandated hold
February 7, 2023Research and Development
4D Molecular Therapeutics has had its gene therapy programme 4D-310 put on clinical hold by the FDA after adverse side …
Strong sales of Basilea’s Cresemba triggers second sales milestone payment from Pfizer
February 7, 2023Sales and Marketing
Swiss commercial-stage biopharmaceutical company Basilea Pharmaceutica Ltd has announced that continued high sales of its drug Cresemba (isavuconazole) in China …
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
February 7, 2023Business Services
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) has accepted …
Oxford Science Enterprises strengthens Life Sciences investment team with appointment of Sanne de Jongh as Partner
February 7, 2023Business Services
Oxford, UK: February 7, 2023 – Oxford Science Enterprises (OSE), the independent investment company created to found, fund and build transformational businesses …
Chong Kun Dang Pharm Licenses Synaffix ADC Technology, Adds Novel ADC Candidate to Oncology Pipeline
February 6, 2023Business Services
THE NETHERLANDS and SOUTH KOREA, 6 February 2023 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform …
Oxford University scientists’ AI diagnostic test accurately identifies known respiratory viruses in minutes
February 6, 2023Business Services
February 6th, 2023 – Oxford, United Kingdom – Nicolas Shiaelis and
Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®
February 6, 2023Business Services
Basel, February 4, 2023 – Novartis announced today that The Lancet has published long-term data from the pivotal SUNSHINE and …
SPR Therapeutics gains FDA extended approval for pain management system
February 6, 2023Research and Development
Pain management medical device company SPR Therapeutics has obtained expanded approval from the FDA for its SPRINT Peripheral Nerve System …
Australia’s TGA approves psychedelics to treat mental health conditions
February 6, 2023Research and Development
Australia’s Therapeutic Goods Administration (TGA) has announced its approval of the use of psychedelics to treat certain mental health conditions. …
Daiichi Sankyo to build Japan’s first factory for mRNA COVID-19 vaccines
February 6, 2023Manufacturing and Production
Daiichi Sankyo have announced its plans to build Japan’s first factory for mRNA COVID-19 vaccines. The new facility is expected …
Boston Scientific fined $42m over patent infringement
February 6, 2023Medical Communications
A five-year legal battle between Boston Scientific and TissueGen has culminated in a $42m fine, which Boston Scientific must pay …
Businesses from the UK are in the top four foreign investors in Flanders in 2022
February 3, 2023Business Services
Investment figures released this week by Flanders Investment & Trade show that UK businesses are continuing to make significant investments …
IMFINZI (DURVALUMAB) IN COMBINATION WITH GEMCITABINE AND CISPLATIN APPROVED IN GREAT BRITAIN AS A FIRST-LINE TREATMENT FOR ADULT PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC BILIARY TRACT CANCER
February 3, 2023Business Services
London, UK, Thursday 2 February 2023 – AstraZeneca today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has …
MHRA Approves RINVOQ®▼ (upadacitinib) as First Oral Advanced Therapy to Treat Adults with Moderately to Severely Active Crohn’s Disease
February 3, 2023Business Services
MAIDENHEAD, UK, 01 February 2023 – AbbVie (NYSE: ABBV) today announced that the UK Medicines and Healthcare products Regulatory Agency …
Phlo raises £10m to spearhead digital transformation in pharmacy sector
February 3, 2023Business Services
[Glasgow, Scotland] Phlo, UK digital pharmacy leaders, have closed a £10m Series A round led by family office Thairm Bio. …
Latest content
FibroFind appoints Lee Borthwick as CEO
